Zika virus infectious disease
Therapeutic area
Infectious Disease
Rare disease
Yes
- Definition
- Mosquito-born virus disease characterized by a clinical course that may be asymptomatic or mild with fever, conjunctivitis, muscle and joint pain, headache, exanthema, but may also be associated with severe neurological (meningitis, meningoencephalitis and myelitis) and auto-immune (Guillain-Barre syndrome) complications, as well as a potential increase of birth defects (microcephaly) if the infection occurs during pregnancy.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Zika virus infectious disease
- Therapeutic area
- Infectious Disease
- Zika virus infectious disease
- ZikV infection
- Zika
- Zika virus caused disease or disorder
- Zika virus disease
- Zika virus disease or disorder
- Zika virus infection
- Zika virus infectious disease
- congenital Zika syndrome
- congenital Zika virus infection
- Zika fever
- fever, Zika
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Severe
- MONDO ID
- MONDO:0018661
- Parent condition
- MONDO:0005763
Related records
Broader conditions (9)
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Flaviviridae infectious disease
- Human disease
- Infectious disease
- Primary viral infectious disease
- Vector-borne disease
- Viral infectious disease
Trials (77)
- A Cluster-randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil (EVITA Dengue)
- A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.
- A Pilot Study Examining for the Presence of Fecal Coliforms and Tropical Diseases in Peru
- A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas
- Adherence to Care for Children With Congenital Zika Virus Infection in Puerto Rico
- Applying Wolbachia to Eliminate Dengue
- Baromètre Santé Adulte 2021-2022
- Cohort of Patients Infected by an Arbovirus
- Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
- Dermatologic Manifestations of Zika Virus
- Effect of a Posture Adapter for 12 to 24-month Children With Zyka Virus Syndrome
- Efficacy of Aquatic Physiotherapy in Children With Microcephaly by Zika Virus Congenital Syndrome
- Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection.
- Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua
- Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA
- Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge
- Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)
- Evaluation of Viral Replication by Tonate Virus (TONV) and Zika Virus (ZIKV), Within an ex Vivo Trophoblast and Placental Model
- Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
- GLS-5700 in Dengue Virus Seropositive Adults
Drugs in development (3)
- Human immunoglobulin G Phase 1
- Sodium chloride Phase 1
- Telratolimod Phase 1